FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust; Division of Cancer Sciences, University of Manchester, Manchester, UK.Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Lamarca A, Foster L, Valle JW, Satyadas T, Siriwardena A. FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out? ESMO Open. 2020;5(5).Journal
ESMO OpenDOI
10.1136/esmoopen-2019-000633PubMed ID
33122352Additional Links
https://dx.doi.org/10.1136/esmoopen-2019-000633Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/esmoopen-2019-000633
Scopus Count
Collections
Related articles
- The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
- Authors: Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M
- Issue date: 2013 Apr
- CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
- Authors: Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB
- Issue date: 2017 Jul
- Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
- Authors: Saif MW, Chabot J
- Issue date: 2011 Jul 5
- Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
- Authors: Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest
- Issue date: 2007 May 1
- Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
- Authors: Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B
- Issue date: 2017 Jun